Does Moderna Need to Start Making Money?
(NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.
However, a lot has changed in the past few years. Although Moderna's COVID-19 vaccines remain its primary revenue stream, sales are just a fraction of what they were during the pandemic. Plus, the company is losing money hand over fist, posting a $2.8 billion net loss in 2025 and expecting billions in losses in 2026 as well.
Based on this, you might think Moderna would be a terrible investment. But I'm not sure that's the case, and there are three main reasons why.
Source Fool.com
Moderna Inc. Aktie
47,52 €
-3,26 %
Die Community ist uneins: 9 Buy- gegen 8 Sell-Einschätzungen bei Moderna Inc..
Trotz eines Kursziels von 21 €, das unter 47.52 € liegt, ergibt sich für Moderna Inc. ein negatives Potenzial von -55.8%.
